Chinese clinical research outfit HD Biosciences has struck a deal with Marshall University to collaborate on cancer drug development, sharing costs and risks in hopes of commercializing new therapies.
The National Cancer Institute is terminating a $34 million mouse-model contract with Charles River Laboratories, possibly imperiling jobs at one of the CRO's Maryland outposts.
CRO inVentiv Health has agreed to share its expertise with the nonprofit Alliance for Clinical Research Excellence and Safety (ACRES), working to develop global standards for clinical trials.
Orthopedic specialist Smith & Nephew will market Blue Belt's surgical knee system in a worldwide agreement that could help breathe fresh life into Smith & Nephew's flagging knee implant revenue growth. The partnership with Smith & Nephew is the startup's first major distribution deal.
Soon, there will be a device to cure some forgetfulness if the Department of Defense's four-year grant of up to $40 million succeeds in fostering implants and electronic interfaces that diagnose and treat memory loss due to traumatic brain injury.
Germany's CureVac will implement its RNA stabilizing RNActive technology in its new collaboration with French firm Sanofi Pasteur to develop a messenger RNA-based vaccine targeting an undisclosed pathogen.
The pact focuses on identifying and selecting novel drug targets with the potential to become potent, selective therapeutics in the areas of oncology, inflammation and diabetes.
Amgen has bowed out of a $180 million collaboration with Cambridge, MA-based Bind Therapeutics, ending work on a new therapy for solid tumors by amping up an Amgen drug with the biotech's nanoengineering technology. News of the research setback--which ends the first big pact inked for the biotech's delivery tech--took a bite out of Bind's shares, sending its stock down by more than 10%.
Sanofi Pasteur and Germany's CureVac first joined up in 2011 with a licensing option agreement for a slew of pathogens. Now, they're beefing up their partnership with another licensing deal, this one giving the French company rights to a new mRNA-based vaccine.
Contract developer Recipharm and CTC Clinical Trial Consultants are joining forces to offer combined Phase I services, pooling their capabilities in manufacturing and trial conduction.